Characterization of T-cell responses against IκBα in cancer patients

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1290-1296

  Munir, Shamaila ^a   Frøsig, Thomas Mørch ^a   Hansen, Morten ^a   Svane, Inge Marie ^a   Andersen, Mads Hald ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

Antigens; CTL; Inhibitor of B; NF B; Proteasome; T cells

Indexed keywords

EPITOPE; GAMMA INTERFERON; GRANZYME B; HISTIDYLLEUCYLALANYLSERYLISOLEUCYLHISTIDYLGLYCYLTYROSYLLEUCINE; HLA A2 ANTIGEN; I KAPPA B ALPHA; PROTEASOME; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER IMMUNOLOGY; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

EID: 84886606126     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21625     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
2. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010; 336:25-37; PMID:19823771; http://dx.doi.org/10.1007/s11010-009-0267-2.
3. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10; PMID:12001991; http://dx.doi.org/10.1038/nrc780.
4. Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, et al. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 2009; 40:795-806; PMID:19157506; http://dx.doi.org/10.1016/j.humpath.2008.10.019.
5. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30:1615-30; PMID:21170083; http://dx.doi.org/10.1038/onc.2010.566.
6. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34; PMID:12360211; http://dx.doi.org/10.1038/nri91.
7. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, et al. Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 2000; 21:871-9; PMID:10783306; http://dx.doi.org/10.1093/carcin/21.5.871.
8. Miyamoto S, Chiao PJ, Verma IM. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol Cell Biol 1994; 14:3276-82; PMID:8164680.
9. Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol 1998; 16:323-58; PMID:9597133; http://dx.doi.org/10.1146/annurev.immunol.16.1.323.
10. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182:323-31; PMID:10653598; http://dx.doi.org/10.1002/(SICI)1097-4652(200003)182:3<323::AIDJCP2> 3.0.CO;2-#.
11. Andersen MH, Tan L, Søndergaard I, Zeuthen J, Elliott T, Haurum JS. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 2000; 55:519-31; PMID:10902608; http://dx.doi.org/10.1034/j.1399-0039.2000.550603.x.
12. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61:869-72; PMID:11221872.
13. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, et al. Identification of known and novel immunogenic T cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 98:409-14; PMID:11920592; http://dx.doi.org/10.1002/ijc.10205.
14. Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 1999; 96:12033-8; PMID:10518571; http://dx.doi.org/10.1073/pnas.96.21.12033.
15. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006; 3:255-61; PMID:16978533.
16. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13:1076-82; PMID:17317814; http://dx.doi.org/10.1158/1078-0432.CCR-06-2221.
17. Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, et al. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011; Epub Ahead of Print; PMID:21732930; http://dx.doi.org/10.1111/j.1365-2141.2011.08791.x.
18. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F, et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006; 25:387-98; PMID:16170348.
19. Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003; 1:14; PMID:14697097; http://dx.doi.org/10.1186/1479-5876-1-14.
20. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al. MHC-restricted fratricide of human lymphocytes expressing survivinspecific transgenic T cell receptors. J Clin Invest 2010; 120:3869-77; PMID:20978348; http://dx.doi.org/10.1172/JCI43437.
21. Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; http://dx.doi.org/10.1182/blood-2010-06-288498.
22. + T cell responses against indoleamine 2,3-dioxygenase. PLoS ONE 2012; 7:e34568; PMID:22539948; http://dx.doi.org/10.1371/journal.pone.0034568.
23. Andersen MH, Sørensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identification of heme oxygenase-1-specific regulatory CD8+ T-cells in cancer patients. J Clin Invest 2009; 119:2245-56; PMID:19662679; http://dx.doi.org/10.1172/JCI38739.
24. Rammensee HG, Falk K, Roetzschke O. MHC molecules as peptide receptors. Curr Opin Immunol 1993; 5:35-44; PMID:7680871; http://dx.doi.org/10.1016/0952-7915(93)90078-7.
25. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210:149-66; PMID:9520298; http://dx.doi.org/10.1016/S0022-1759(97)00182-8.
26. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999; 163:3812-8; PMID:10490979.
27. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51; PMID:16462803; http://dx.doi.org/10.1038/nm1360.
28. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006; 1:1120-32; PMID:17406393; http://dx.doi.org/10.1038/nprot.2006.121.